Latest news, reports, and more from the RedChip Nation.
 
 
 >
Level Brands Completes Name Change and Begins Trading Under YCBD Ticker
 
 

Level Brands completed its plan name change to cbdMD (NYSE American: YCBD) last week and began trading on the NYSE American under the ticker symbol YCBD at the open of trading on May 1.

 

Why It Matters: A company of firsts, YCBD is not only the first CBD company to trade on the NYSE American, they were also the first to advertise in Times Square and the first to advertise in Rolling Stone and ELLE magazines. The company’s new ticker ticker represents cbdMD as the consistent leader and innovator in this booming market.

 

Key Quote: “We are making history today. cbdMD continues to lead the way in America's CBD industry. On behalf of all of our employees, I look forward to updating you on this exciting company during our quarterly earnings call in May.” – Martin Sumichrast, Chairman

 

The Backstory: With a strong cash position and the benefit of the expected increase in major retailer acceptance from the passage of the 2018 Farm Bill, cbdMD believes it can accelerate revenue growth in the rapidly expanding CBD market. The Company has set targets of more than $20 million in revenue for 2019 and more than $300 million in aggregate revenue over the next five years. Peers in the CBD space command high multiples, trading for an average price-to-sales ratio of more than 60x. Comparatively, cbdMD currently trades for around 20x its trailing 12-month sales. Quarterly and monthly sales have been increasing sequentially at a rapid rate, with $5 million in revenue expected for the quarter ended March 31, putting the company in a great position to achieve its 2019 revenue target of $20 million.

 

Analysts at ThinkEquity initiated coverage of the company in March, with a price target of $8 per share. The stock is up nearly 100% year-to-date, trading around $6 per share in recent weeks. Learn more about YCBD by reading RedChip's research on this exciting opportunity. www.ycbdinfo.com/LEVB_Research.pdf

 

Disclosure

cbdMD (NYSE American: YCBD) is a client of RedChip Companies. YCBD agreed to pay RedChip a monthly cash fee of between $5,000 and $15,000, and 5,000 shares of Rule 144 stock for RedChip investor awareness services. Additionally, the CEO of RedChip Companies owns 13,500 shares of YCBD.

 
 
 
 >
Piedmont Lithium (NASDAQ: PLL) Limited March 2019 Quarterly Report
 
 

• Continued the 25,000-meter Phase 4 drill program, with three drill rigs active on the Core property, where a total of 69 holes have been completed to-date. An additional 15 holes have been completed on the Central property, including the Project’s best hole to date: 43.2m @ 1.73% Li2O.

 

• Increased overall land position of the Project by 52% to 2,105 acres. The Company’s Core property now comprises 1,004 acres, representing an 86% increase from the Core property land position underlying the maiden Mineral Resource estimate.

 

• Completed an initial Mineral Resource estimate for the Central property, located approximately one mile south of the Core property, increasing the Project’s total Mineral Resources to 19.0 million tonnes (“Mt”) at 1.15% Li2O.

 

• Submitted key permit applications for the Project, including a Section 404 Standard Individual Permit application to the US Army Corps of Engineers (“USACE”) and a Section 401 Individual Water Quality Certification to the North Carolina Division of Water Resources (“NCDWR”).

 

The Backstory: Piedmont Lithium Limited (Nasdaq: PLL; ASX: PLL) holds a 100% interest in the Piedmont Lithium Project (“Project”) located within the world-class Carolina Tin-Spodumene Belt (“TSB”) and along trend to the Hallman Beam and Kings Mountain mines, historically providing most of the western world’s lithium between the 1950s and the 1980s. The TSB has been described as one of the largest lithium provinces in the world and is located approximately 25 miles west of Charlotte, North Carolina. It is a premier location for development of an integrated lithium business based on its favorable geology, proven metallurgy and easy access to infrastructure, power, R&D centers for lithium and battery storage, major high-tech population centers and downstream lithium processing facilities.

 

Disclosure

Piedmont Lithium (PLL) is a client of RedChip Companies, Inc. PLL agreed to pay RedChip Companies, Inc. a monthly cash fee for six (6) months of RedChip investor awareness services.

 
 
 
 >
Nemaura Medical (NASDAQ: NMRD) Announces Open-Source Software for SugarBEAT®
 
 

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, announced it will allow third-party applications, such as diabetes management, exercise and nutrition focused apps royalty free access to SugarBEAT® CGM app data.

 

Why It Matters: Users will be able to directly access SugarBEAT® generated glucose data through their preferred participating mobile applications, empowering users with greater choice over when to use this data to better understand how food choices and other lifestyle factors impact glucose levels. This development is part of the Company’s broader go-to-market strategy, which is being led by Dr. Fred Schaebsdau. Dr. Schaebsdau joined the Company earlier this year to advance the commercialization and business development of SugarBEAT®, building on his success with earlier CGM products at Abbott Diabetes Care and Dexcom Germany.

 

Key Quote: “We believe integrating SugarBEAT® data into the leading health and fitness apps will help to expand our target market among health-conscious consumers, providing them with seamless access to their CGM data within a familiar environment, which will assist in understanding how diet, sleep, stress, exercise and other lifestyle factors can impact glucose levels.” –Dr. Fred Schaebsdau

 

Disclosure

Nemaura Medical (NASDAQ: NMRD) is a client of RedChip Companies. NMRD agreed to pay RedChip a monthly cash fee for investor awareness services.

 
 
 
 >
Catasys (NASDAQ: CATS) Schedules 2019 First Quarter Financial Results Conference Call for May 9, 2019
 
 

Catasys, Inc. (NASDAQ: CATS), a leading AI and technology-enabled healthcare company, announced that the Company will be releasing financial results for its first quarter ended March 31, 2019, after the closing of the stock market on Thursday, May 9, 2019.

 

The Company will also host a conference call/webcast that same day at 4:30 pm ET/1:30 pm PT.

 

Investors, analysts, employees and the general public are invited to listen to the conference call via:

 

Conference Call

 

877-705-2969 (domestic) or 201-689-8868 (international)

 

What’s Next: Company generated record revenue of $15.2 million in FY18, up 96.7%YoY. Going forward, the Company reiterates 2019 GAAP revenue guidance of $35 million.

 

The Backstory: Catasys, Inc. harnesses proprietary big data predictive analytics, artificial intelligence and telehealth, and human intervention to deliver improved member health and cost savings to health plans through integrated technology enabled treatment solutions. It is our mission to provide access to affordable and effective care, thereby improving health and reducing cost of care for people who suffer from the medical consequences of behavioral health conditions. Catasys helps these people and their families achieve and maintain better lives.

 

Disclosure

Catasys (NASDAQ: CATS) is a client of RedChip Companies, Inc. CATS agreed to pay RedChip Companies, Inc. a monthly cash fee for RedChip investor awareness services and consulting services.

 
 
 
 >
Valeritas (NASDAQ: VLRX) Expects First Quarter Revenue of $6.4 million
 

 

Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, announced it expects to report revenue of approximately $6.4 million for the first quarter ended March 31, 2019. In addition, Valeritas does not expect any significant changes from its first quarter 2019 guidance that it released on March 5, 2019, as the Company will achieve all metrics it provided guidance on for the quarter. Valeritas intends to report its full first quarter 2019 financial results on May 9, 2019.

 

Key Quote: “I am very pleased with the first quarter results and all signs currently indicate this momentum should continue throughout 2019,” said John Timberlake, President and CEO of Valeritas

 

The Backstory: Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, affordable, all-in-one basal-bolus insulin delivery option for patients with type 2 diabetes that is worn like a patch and can eliminate the need for taking multiple daily shots. V-Go administers a continuous preset basal rate of insulin over 24 hours, and it provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Marlborough, Massachusetts.

 

 
 
 
 >
Electra Meccanica (NASDAQ:SOLO) Obtains Vehicle Consumer Rebate Designation From California Air Resources Board (CARB)
 
 

Electra Meccanica Vehicles Corp. (SOLO) (“Electra Meccanica” or the “Company”), a designer and manufacturer of electric vehicles, announced that the Company has received approval to participate in the Clean Vehicle Rebate Project, which will provide consumers who purchase a new SOLO EV in California with a $900 per vehicle rebate.

 

Key Quote: This is a significant milestone for both the company and consumers throughout California,” explains Jerry Kroll, CEO of Electra Meccanica

 

The Backstory: Electra Meccanica is a designer and manufacturer of electric vehicles. The Company builds the innovative, all-electric SOLO, a single passenger vehicle developed to revolutionize the way people commute, as well as the Tofino, an elegant high-performance two-seater electric roadster sports car. Both vehicles are tuned for the ultimate driving experience while making your commute more efficient, cost-effective and environmentally friendly. Intermeccanica, a subsidiary of Electra Meccanica, has successfully been building high-end specialty cars for 60 years. For more information, visit www.electrameccanica.com.

 

 
 
 
 >
Emerald Health (OTCQX: EMHTF) Reports Q4 Results
 
 

Emerald Health Therapeutics (OTCQX: EMHTF) reported sales up 300% to $1.1 million in the fourth quarter and guided for $2.6 million in first quarter sales.

 

Key Quote: “In the past year we have worked closely with our 50/50 venture partner to bring into full production one of the single largest cannabis growing assets in the world. Pure Sunfarms’ 1.1 million square foot facility is now rapidly increasing production and sales. By leveraging our own technical expertise and infrastructure with strong partners in 2018, we solidified key building blocks with respect to production/supply, distribution, processing in the form of large-scale extraction, softgel encapsulation, and product innovation.” – Dr. Avtar Dhillon, President and Executive Chairman

 

 
 
 
 >
eMARINE Global (OTC: EMRN) Receives “Best Technology” Award
 
 

eMARINE Global (OTC: EMRN), a leading provider of information and communications technology (ICT) for the maritime industry, was awarded a “Certificate of Best Technology 2019” from the Seoul Credit & Information Tech Credit Bureau (SCI TCB).

 

Why it Matters: The SCI TCB is a public evaluation bureau that rates companies across all industries in South Korea. The agency rates companies using a scale from T1 to T10, with T1 representing the strongest companies. SCI TCB issued eMARINE a T4 rating, regarded as the best level for smaller, growing companies, citing the company’s technology edge in electronic charting and application development.

 

Key Quote: “The certificate and T4 rating from SCI TCB are important benchmarks evaluated by potential banking and business partners. We are very proud of being publicly recognized for our core technical competence and plan to capitalize on our standing in the business community as we move forward.” - Ung Gyu Kim, Chairman and CEO

 

Disclosure

eMARINE Global (OTC: EMRN) is a client of RedChip Companies. RedChip Companies, Inc. owns 613,000 shares of EMRN common stock.

 
 
 
 >
Santa Fe Gold (OTC: SFEG) Commences Operations at Steeple Rock District Gold & Silver Mine
 
 

Santa Fe Gold (OTC: SFEG), a U.S. based mining company and owner of 148 mining claims covering 42 mine sites and potential mines, announced the commencement of ore production from its Jim Crow mine located in the historic Steeple Rock mining district of southwest New Mexico.

 

Key Quote: “We are very pleased with our overall achievements to date to be able to announce commencement of production of ore on schedule, having made what we believe to be considerable progress to this point.” – Brian Adair, Chairman

 

What’s Next: Potential for developing additional mineralized resources within the Jim Crow Mine and in the adjacent Imperial Mine exists in multiple directions. In addition to the Jim Crow Vein itself which is undeveloped both laterally and at depth, we believe there are two parallel veins showing potential economic grades and widths. Long term planning and expansion of production is expected to continue pending the development of sufficient ore within these three properties. The anticipated sale of the developmental “ore” from early production from the Jim Crow mine should offer a degree of mining flexibility to substantially expand ongoing development of this project.

 

Disclosure

Santa Fe Gold Corp. (OTC: SFEG) is a client of RedChip Companies, Inc. SFEG agreed to pay RedChip Companies, Inc. 1,000,000 shares of Rule 144 stock for 12 months of RedChip investor awareness services and consulting services.

 

 
 
 
 
Quote of the Week
 
"Do your homework, understand companies you invest in forwards and backwards."
- Charles Diker, Diker Management-Microcap Superstar
 
 
 
Lesson of the Week
 
Microcap pros make millions by buying before the crowd.
Read More
 
 
 
 
Latest Videos
 
 
 
 
Two NASDAQ Stocks Trading Well Below Wall Street Price Targets
 
Watch the latest episode of the RedChip Money Report featuring interviews with executives of two undervalued NASDAQ companies. Piedmont Lithium (NASDAQ: PLL) and MYnd Analytics (NASDAQ: MYND).
 
Watch Now
 
 
 
 
Piedmont Lithium: Only Conventional US Lithium Development Project
 
Exclusive interview with Keith Phillips, President & CEO of Piedmont Lithium (NASDAQ: PLL). Learn about PLL's domestic lithium project, including the multiple near-term catalysts that could drive shares higher.
 
Watch Now
 
 
 
 
Emerald Health: Growing Operations in Multi-Billion-Dollar Markets Globally
 
Exclusive interview with Rob Hill, CEO of Emerald Health (OTCQX: EMHTF), a Canadian licensed producer of cannabis with large-scale grow, extraction, and production capacity.
 
Watch Now
 
 
 
 
MYnd Analytics: Game-Changing AI & Telemedicine Solution for $130B Behavioral Health Market
 
Game-changing big data tech combined with telemedicine and the upside of an FDA-approved drug.
 
Watch Now
 
 
 
 
Rapidly Growing Green Stock in a Multi-Billion-Dollar Market
 
Exclusive interview with GSRX Industries' Chairman Christian Briggs, who discusses the company's rapid growth in the markets for legal medical/recreational marijuana and CBD.
 
Watch Now
 
 
 
 
Sharps Provensa: New Smart Safety Syringe from Sharps Technology
 
Sharps Technology is an innovative medical device company, introducing a portfolio of new safety syringes and safety products with a patented single-use mechanism. This game-changing sheath technology is designed to eliminate infectious needlestick injuries.
 
Watch Now
 
 
 
 
Marker Therapeutics: Next Major Leap in T Cell-Based Immunotherapies for Cancer
 
Exclusive interview with Marker Therapeutics’ (NASDAQ: MRKR) Chief Development Officer Dr. Juan Vera. MRKR is in multiple active Phase 2 clinical trials in the $100+ billion market for immunotherapy cancer drugs. MRKR’s Multi-Antigen Targeted Cell Therapy Platform and Peptide Vaccine Portfolio has the potential to disrupt the CAR-T and TCR filed therapies.
 
Watch Now
 
 
 
 
Electra Meccanica: Sales Growing for Innovative 1- and 2-Seat Electric Vehicles
 
Exclusive interview with Electra Meccanica Vehicles’ (NASDAQ: SOLO) Founder & CEO Jerry Kroll. Drawing on a 59-year history of designing, building and delivering high end specialty cars, SOLO has designed and built the innovative, all electric SOLO, single-seater electric vehicle. The Company began delivering electric vehicles in 2018 and booked in excess of 60,000 pre-orders. The Company expects to deliver $77M worth of cars in 2019.
 
Watch Now
 
 
 
 
Tenax Therapeutics (NASDAQ: TENX): Near-Term Phase 2 Results Expected to Drive Stock
 
Exclusive interview with Tenax Therapeutics (NASDAQ: TENX) CEO Anthony Ditonno.TENX is expected to report Phase 2 results for its pulmonary hypertension treatment by year end. Its innovative treatment is based on an established compound, approved in 60+ countries and cited in 1000+ publications, which provides a strong foundation that de-risks the development opportunity.
 
Watch Now
 
 
 
 
Polar Power: Innovative Power Solutions for Critical Applications
 
Exclusive interview with Polar Power (NASDAQ: POLA) CEO Arthur Sams. POLA is expected to report record revenue for Q4 2018, driven by increased production capacity and service infrastructure. Revenue growth is expected to accelerate in 2019.
 
Watch Now
 
 
 
 
Order Small Stocks, Big Money Today!
 
Dave Gentry is the author of Small Stocks, Big Money: Interviews With Microcap Superstars. Published by Wiley, this first-hand perspective on the fast world of microcap investing is now available for purchase.
 
 
MidSouth Week in Review
 
The Fed elected to not lower interest rates in spite of some signs of inflation easing.
Read More
 
 
Weekly Index Performance
 
Small-cap indexes posted gains last week, while larger caps were virtually unchanged.
Read More
 
About RedChip
 
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
 
RedChip Disclosure
 
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and view RedChip’s Disclosures.
 
 
     
 
 
Copyright © 2019 RedChip Companies, Inc. All Rights Reserved.